menu

Loading...

OBIO Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.665

Open

4.510

VWAP

4.60

Vol

38.74K

Mkt Cap

246.19M

Low

4.480

Amount

178.33K

EV/EBITDA(TTM)

--

Total Shares

56.46M

EV

164.57M

EV/OCF(TTM)

--

P/S(TTM)

64.55

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Show More

Events Timeline

(ET)

2026-01-12

09:10:00

Orchestra BioMed Expects $21 Million Cash from Vivasure Acquisition

2025-11-10 (ET)

2025-11-10

16:48:58

Orchestra BioMed Announces Q3 Earnings Per Share of 40 Cents, Below Consensus Estimate of 43 Cents

2025-10-28 (ET)

2025-10-28

08:17:56

Orchestra BioMed and Terumo Forge New $30M Agreements for Virtue SAB

2025-10-27 (ET)

2025-10-27

09:03:10

Orchestra BioMed Reports Initial Patient Enrollments in Virtue SAB Study

2025-09-04 (ET)

2025-09-04

17:03:45

Orchestra BioMed Reveals Latest Findings from AVIM Therapy Initiative

News

Globenewswire

2025-12-08Globenewswire

Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development for Hypertension

Newsfilter

2025-12-08Newsfilter

Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development

Newsfilter

2025-11-26Newsfilter

Orchestra BioMed Grants 151,250 Stock Options to 12 New Employees

Newsfilter

2025-11-11Newsfilter

Orchestra BioMed to Attend Upcoming Conferences for Institutional Investors

NASDAQ.COM

2025-11-10NASDAQ.COM

Orchestra BioMed Holdings Reports Increased Loss in Q3

SeekingAlpha

2025-11-03SeekingAlpha

Orchestra BioMed announces secondary offering of approximately 8 million shares

4 Analyst Rating

Wall Street analysts forecast OBIO stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.00

Averages

14.25

High

20.00

Current: 0.000

Low

10.00

Averages

14.25

High

20.00

Barclays

Matt Miksic

maintain

$11 -> $12

AI Analysis

2026-01-09

Reason

Barclays

Matt Miksic

Price Target

$11 -> $12

AI Analysis

2026-01-09

maintain

Reason

Barclays analyst Matt Miksic raised the firm's price target on Orchestra BioMed to $12 from $11 and keeps an Overweight rating on the shares. The firm updated the company's model.

TD Cowen

Joshua Jennings

Buy

initiated

$15

2025-12-10

Reason

TD Cowen

Joshua Jennings

Price Target

$15

2025-12-10

initiated

Buy

Reason

TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. Orchestra BioMed is building a differentiated, royalty-based Med Tech model anchored by Atrioventricular Interval Modulation therapy for hypertension and Virtue SAB for arterial atherosclerotic disease, with both programs targeting large, underserved markets, leverage blue-chip partners, and offering scalable, high-margin economics as pivotal data and commercialization milestones approach, the analyst tells investors in a research note. These two assets position Orchestra BioMed at the leading edge of cardiovascular device innovation, the firm argues.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OBIO

Unlock Now

Valuation Metrics

The current forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO.O) is -2.73, compared to its 5-year average forward P/E of -2.79. For a more detailed relative valuation and DCF analysis to assess Orchestra Biomed Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.79

Current PE

-2.73

Overvalued PE

-0.31

Undervalued PE

-5.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.28

Current EV/EBITDA

-1.95

Overvalued EV/EBITDA

0.64

Undervalued EV/EBITDA

-3.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

58.90

Current PS

77.98

Overvalued PS

107.15

Undervalued PS

10.65

Financials

AI Analysis

Annual

Quarterly

Whales Holding OBIO

Perceptive Advisors LLC

RTW Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Orchestra Biomed Holdings Inc (OBIO) stock price today?

The current price of OBIO is 4.665 USD — it has increased 7

What is Orchestra Biomed Holdings Inc (OBIO)'s business?

Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

What is the price predicton of OBIO Stock?

Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is14.25 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Orchestra Biomed Holdings Inc (OBIO)'s revenue for the last quarter?

Orchestra Biomed Holdings Inc revenue for the last quarter amounts to 861.00K USD, decreased -12.77

What is Orchestra Biomed Holdings Inc (OBIO)'s earnings per share (EPS) for the last quarter?

Orchestra Biomed Holdings Inc. EPS for the last quarter amounts to -0.40 USD, decreased -2.44

How many employees does Orchestra Biomed Holdings Inc (OBIO). have?

Orchestra Biomed Holdings Inc (OBIO) has 70 emplpoyees as of March 04 2026.

What is Orchestra Biomed Holdings Inc (OBIO) market cap?

Today OBIO has the market capitalization of 246.19M USD.